Oruka Therapeutics (ORKA) Income from Continuing Operations (2010 - 2024)
Oruka Therapeutics (ORKA) posted quarterly Income from Continuing Operations of 18078000.0 for Q2 2024, down 1085.44% year-over-year from 1834505.59 in Q3 2023, and down 157.93% quarter-over-quarter from 7009000.0 in Q1 2024.
Powered by 
Analysis
Oruka Therapeutics (ORKA) Income from Continuing Operations (2010 - 2024) Analysis & Trends
Oruka Therapeutics' Income from Continuing Operations history runs 15 years deep, the most recent figure standing at 18078000.0 for Q2 2024.
- In Q2 2024, Income from Continuing Operations fell 1085.44% year-over-year to 18078000.0; the TTM figure through Jun 2024 stood at 27966000.0 (down 332.04% YoY), while the FY2023 annual figure was 60870000.0, up 5.32% from the prior year.
- Income from Continuing Operations for Q2 2024 stood at 18078000.0, down from 7009000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1115000.0 in Q4 2023, with the low at 18078000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 2848500.0 (2022), against an average of 3921166.67.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations soared 79.32% in 2022, then tumbled 1085.44% in 2024.
- Oruka Therapeutics' Income from Continuing Operations stood at 5244000.0 in 2020, then retreated by 8.24% to 5676000.0 in 2021, then jumped by 79.32% to 1174000.0 in 2022, then increased by 5.03% to 1115000.0 in 2023, then slumped by 1521.35% to 18078000.0 in 2024.
- Business Quant data shows ORKA's Income from Continuing Operations at 18078000.0 in Q2 2024, 7009000.0 in Q1 2024, and 1115000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Oruka Therapeutics | 5.85 Bn | 4.12 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -2.68 Mn |
| Mar 31, 2024 | -2.01 Mn |
| Dec 31, 2023 | -1.09 Mn |
| Sep 30, 2023 | -1.42 Mn |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -1.17 Mn |
| Sep 30, 2022 | -2.33 Mn |
| Jun 30, 2022 | -3.15 Mn |
| Mar 31, 2022 | -3.27 Mn |
| Dec 31, 2021 | -5.68 Mn |
| Sep 30, 2021 | -4.71 Mn |
| Jun 30, 2021 | -4.83 Mn |
| Mar 31, 2021 | -4.10 Mn |
| Dec 31, 2020 | -3.09 Mn |
| Sep 30, 2020 | -1.99 Mn |
| Jun 30, 2020 | -1.30 Mn |
| Mar 31, 2020 | -1.32 Mn |
| Dec 31, 2019 | -242,000.00 |
| Sep 30, 2019 | -1.16 Mn |